Orthocell (ASX:OCC) has locked in a U.S. distributor deal for its flagship product and biotech punter favourite Remplir, leaving the company confident U.S. sales are about to kick off.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The company, up over +200% YoY as part of a recent wave of biotech hopefuls making strides with the FDA, has managed to eke its way through the top-heavy approvals system in the #1 economy.
Once you get past that long-spanning process, the question then becomes, okay, now how do we sell our product? That’s what investors on HotCopper have been discussing with regard to Orthocell, and it is those ponderous minds Orthocell has sought to reassure on Wednesday.
“We have been working closely with a number of distributors in the United States … and welcome them on board as our first partners,” company CEO Paul Anderson said.
“The distributor model… allows us to partner with distributors that have existing strong relationships and established sales channels with both surgeons and hospitals.”
You’d hope so.
At any rate, its Remplir product – a collagen-based nerve wrap applied to nerve endings damaged by other surgeries or accidents – stands to be a pretty good money maker in the minds of many. That’s evidenced by the company’s one-year returns.
And sitting on $31M in cash, Orthocell reckons it’s all good to go as far as launching into US sales goes. It’d be a shame if they had to capital raise any time soon – suggesting the company has a good idea of how to manage expectations.
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
Of course, a distributor deal isn’t as good as an NPAT forecast beat. Investors will just need to wait for that. Or make a lot of phone calls.
OCC last traded at $1.18/sh.
Join the discussion: See what HotCopper users are saying about Orthocell and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.